Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 48.0%

Neg 48% Neu 0% Pos 0%

Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $19 to $17.